IL219051A - Methods for predicting clinical outcome of cancer - Google Patents
Methods for predicting clinical outcome of cancerInfo
- Publication number
- IL219051A IL219051A IL219051A IL21905112A IL219051A IL 219051 A IL219051 A IL 219051A IL 219051 A IL219051 A IL 219051A IL 21905112 A IL21905112 A IL 21905112A IL 219051 A IL219051 A IL 219051A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- methods
- clinical outcome
- predict clinical
- predict
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26376309P | 2009-11-23 | 2009-11-23 | |
| PCT/US2010/057490 WO2011063274A2 (en) | 2009-11-23 | 2010-11-19 | Methods to predict clinical outcome of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL219051A0 IL219051A0 (en) | 2012-06-28 |
| IL219051A true IL219051A (en) | 2016-12-29 |
Family
ID=44060376
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL219051A IL219051A (en) | 2009-11-23 | 2012-04-04 | Methods for predicting clinical outcome of cancer |
| IL249159A IL249159A0 (en) | 2009-11-23 | 2016-11-23 | Methods for predicting clinical outcome of cancer |
| IL257063A IL257063B (en) | 2009-11-23 | 2018-01-21 | Methods for predicting clinical outcome of cancer |
| IL264072A IL264072B (en) | 2009-11-23 | 2019-01-03 | Methods for predicting clinical outcome of cancer |
| IL276487A IL276487B (en) | 2009-11-23 | 2020-08-04 | Methods for predicting clinical outcome of cancer |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249159A IL249159A0 (en) | 2009-11-23 | 2016-11-23 | Methods for predicting clinical outcome of cancer |
| IL257063A IL257063B (en) | 2009-11-23 | 2018-01-21 | Methods for predicting clinical outcome of cancer |
| IL264072A IL264072B (en) | 2009-11-23 | 2019-01-03 | Methods for predicting clinical outcome of cancer |
| IL276487A IL276487B (en) | 2009-11-23 | 2020-08-04 | Methods for predicting clinical outcome of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20110123990A1 (cg-RX-API-DMAC7.html) |
| EP (4) | EP4350001A3 (cg-RX-API-DMAC7.html) |
| JP (7) | JP5964752B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010321829B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2776751C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2504451T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2735993T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE044374T2 (cg-RX-API-DMAC7.html) |
| IL (5) | IL219051A (cg-RX-API-DMAC7.html) |
| MX (3) | MX391499B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ599194A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2504451T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011063274A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| EP2163650B1 (en) | 2004-04-09 | 2015-08-05 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| PL1836629T3 (pl) * | 2004-11-05 | 2020-06-15 | Genomic Health, Inc. | Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu |
| US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| CN102132160A (zh) * | 2008-06-26 | 2011-07-20 | 达纳-法伯癌症研究院有限公司 | 与转移有关的信号和决定子以及它们的使用方法及用途 |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| AU2010321829B2 (en) * | 2009-11-23 | 2015-07-30 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
| NZ705645A (en) | 2010-01-11 | 2016-05-27 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| SG186940A1 (en) | 2010-07-27 | 2013-02-28 | Genomic Health Inc | Method for using gene expression to determine prognosis of prostate cancer |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| US20140113297A1 (en) * | 2011-03-26 | 2014-04-24 | Oregon Health & Science University | Gene expression predictors of cancer prognosis |
| WO2012178087A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| WO2013006495A2 (en) * | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| KR102003660B1 (ko) * | 2011-07-13 | 2019-07-24 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 데이터 수집 및 분배 방법 |
| WO2013025952A2 (en) * | 2011-08-16 | 2013-02-21 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of breast cancer |
| EP2776830B1 (en) * | 2011-11-08 | 2018-05-09 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| JP5805518B2 (ja) * | 2011-12-21 | 2015-11-04 | 株式会社島津製作所 | マルチプレックス大腸がんマーカーパネル |
| HK1201881A1 (en) | 2012-01-31 | 2015-09-11 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| WO2013159099A2 (en) * | 2012-04-20 | 2013-10-24 | Memorial Sloan-Kettering Cancer Center | Gene expression profiles associated with metastatic breast cancer |
| US20150299799A1 (en) | 2012-10-05 | 2015-10-22 | Michael Sturzl | Method for Detecting an Increased Risk or Incidence of Colorectal Cancer |
| CA2891653A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| KR101672531B1 (ko) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 |
| WO2014194078A1 (en) * | 2013-05-30 | 2014-12-04 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| US10392667B2 (en) * | 2013-06-07 | 2019-08-27 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| US20170073763A1 (en) * | 2014-03-12 | 2017-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| WO2016092299A1 (en) * | 2014-12-09 | 2016-06-16 | Medical Research Council | Methods and kits for predicting the response to therapy of cancer |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| AU2016343937B2 (en) | 2015-10-30 | 2023-01-19 | Exact Sciences Corporation | Multiplex amplification detection assay and isolation and detection of DNA from plasma |
| CA3008273A1 (en) | 2015-12-18 | 2017-06-22 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| US11680298B2 (en) | 2016-09-07 | 2023-06-20 | Agency For Science, Technology And Research | Method of identifying risk of cancer and therapeutic options |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| EP3574110A4 (en) | 2017-01-27 | 2021-01-13 | Exact Sciences Development Company, LLC | DETECTION OF COLUMN NEOPLASIA BY ANALYSIS OF METHYLATED DNA |
| WO2018212192A1 (ja) * | 2017-05-18 | 2018-11-22 | 京都府公立大学法人 | 癌の予後及び／又は転移可能性を評価する方法及びマーカー |
| US12275994B2 (en) * | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| KR102424222B1 (ko) | 2017-11-13 | 2022-07-21 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스 |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| US11198911B2 (en) * | 2018-03-08 | 2021-12-14 | University Of Notre Dame Du Lac | Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon |
| JP7199045B2 (ja) * | 2018-04-13 | 2023-01-05 | 国立大学法人大阪大学 | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム |
| JP7444376B2 (ja) * | 2018-09-21 | 2024-03-06 | 国立大学法人 東京大学 | がんの予後判定方法 |
| JP2019032334A (ja) * | 2018-10-03 | 2019-02-28 | イムノヴィア・アクチエボラーグ | 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ |
| KR102216645B1 (ko) * | 2018-10-29 | 2021-02-17 | 사회복지법인 삼성생명공익재단 | 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도 |
| JP2022512152A (ja) * | 2018-12-08 | 2022-02-02 | ピーエフエス・ジェノミクス・インコーポレイテッド | 乳がんの予後についてのトランスクリプトームプロファイリング |
| JP7584151B2 (ja) * | 2019-05-03 | 2024-11-15 | ディーシージェン カンパニー リミテッド | 癌の予後予測方法およびその組成物 |
| CN111235270B (zh) * | 2019-08-29 | 2022-04-29 | 北京臻知医学科技有限责任公司 | 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒 |
| US12165747B2 (en) * | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2022174089A1 (en) * | 2021-02-12 | 2022-08-18 | Mammogen, Inc. | Biomarkers for the diagnosis of breast cancer |
| WO2022192128A2 (en) * | 2021-03-08 | 2022-09-15 | Castle Biosciences, Inc. | Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores |
| CN117116345B (zh) * | 2023-07-24 | 2025-09-16 | 中国人民解放军军事科学院军事医学研究院 | 一种基于基因调控网络构建患者生存网络的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| US7514209B2 (en) * | 2001-06-18 | 2009-04-07 | Rosetta Inpharmatics Llc | Diagnosis and prognosis of breast cancer patients |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| ATE529535T1 (de) * | 2002-03-13 | 2011-11-15 | Genomic Health Inc | Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe |
| US20040067234A1 (en) * | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| EP3330875B1 (en) * | 2003-07-10 | 2021-12-01 | Genomic Health, Inc. | Expression profile algorithm and test for prognosing breast cancer recurrence |
| JP2007527247A (ja) * | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| US20080299550A1 (en) * | 2004-09-20 | 2008-12-04 | Bayer Healthcare Ag | Methods and Kits For the Prediction of Therapeutic Success and Recurrence Free Survival In Cancer Therapy |
| WO2006103442A2 (en) * | 2005-04-01 | 2006-10-05 | Ncc Technology Ventures Pte. Ltd. | Materials and methods relating to breast cancer classification |
| WO2006133460A2 (en) * | 2005-06-09 | 2006-12-14 | Yale University | Methods for diagnosing and treating breast cancer based on a her/er ratio |
| AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| TWI304443B (en) * | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| US7888019B2 (en) * | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
| EP2140025A2 (en) * | 2007-04-16 | 2010-01-06 | Ipsogen | Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer |
| WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
| WO2009095319A1 (en) * | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
| WO2009132928A2 (en) * | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
| ES2403220T3 (es) * | 2008-05-12 | 2013-05-16 | Genomic Health, Inc. | Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia |
| AU2010321829B2 (en) * | 2009-11-23 | 2015-07-30 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
-
2010
- 2010-11-19 AU AU2010321829A patent/AU2010321829B2/en active Active
- 2010-11-19 ES ES10832289T patent/ES2735993T3/es active Active
- 2010-11-19 US US12/950,732 patent/US20110123990A1/en not_active Abandoned
- 2010-11-19 MX MX2019003811A patent/MX391499B/es unknown
- 2010-11-19 MX MX2016003089A patent/MX363817B/es unknown
- 2010-11-19 HU HUE10832289 patent/HUE044374T2/hu unknown
- 2010-11-19 CA CA2776751A patent/CA2776751C/en active Active
- 2010-11-19 NZ NZ599194A patent/NZ599194A/en unknown
- 2010-11-19 WO PCT/US2010/057490 patent/WO2011063274A2/en not_active Ceased
- 2010-11-19 PL PL10832289T patent/PL2504451T3/pl unknown
- 2010-11-19 EP EP23213439.5A patent/EP4350001A3/en active Pending
- 2010-11-19 CA CA3043089A patent/CA3043089A1/en not_active Withdrawn
- 2010-11-19 EP EP19175741.8A patent/EP3556867A1/en not_active Withdrawn
- 2010-11-19 EP EP10832289.2A patent/EP2504451B1/en active Active
- 2010-11-19 MX MX2012005822A patent/MX337650B/es active IP Right Grant
- 2010-11-19 JP JP2012540103A patent/JP5964752B2/ja active Active
- 2010-11-19 EP EP20177718.2A patent/EP3739060A1/en not_active Withdrawn
- 2010-11-19 DK DK10832289.2T patent/DK2504451T3/da active
-
2012
- 2012-04-04 IL IL219051A patent/IL219051A/en active IP Right Grant
-
2016
- 2016-06-30 JP JP2016129697A patent/JP2016214245A/ja active Pending
- 2016-11-23 IL IL249159A patent/IL249159A0/en unknown
-
2017
- 2017-02-03 US US15/423,977 patent/US20170211154A1/en not_active Abandoned
-
2018
- 2018-01-21 IL IL257063A patent/IL257063B/en active IP Right Grant
- 2018-08-02 JP JP2018145578A patent/JP7042717B2/ja active Active
-
2019
- 2019-01-03 IL IL264072A patent/IL264072B/en active IP Right Grant
- 2019-01-09 US US16/243,207 patent/US20190241967A1/en not_active Abandoned
-
2020
- 2020-08-04 IL IL276487A patent/IL276487B/en unknown
- 2020-09-11 US US17/018,143 patent/US20210062275A1/en not_active Abandoned
- 2020-12-28 JP JP2020218527A patent/JP2021058207A/ja active Pending
-
2022
- 2022-08-02 JP JP2022123265A patent/JP2022166064A/ja active Pending
- 2022-08-16 JP JP2022129605A patent/JP2022169647A/ja active Pending
-
2023
- 2023-12-18 JP JP2023213416A patent/JP2024037948A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276487B (en) | Methods for predicting clinical outcome of cancer | |
| IL276362A (en) | Cancer treatment methods | |
| IL256335B (en) | A method for using gene expression to determine the likelihood of clinical outcome in kidney cancer | |
| IL218575A0 (en) | Treatment of cancer | |
| ZA201206019B (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
| PL2297359T3 (pl) | Profile ekspresji genów do przewidywania skutków raka piersi | |
| EP2438197A4 (en) | METHOD OF CANCER DETECTION | |
| IL223189A0 (en) | Methods of treatment of pancreatic cancer | |
| PL2435825T3 (pl) | Sposoby leczenia chorób | |
| EP2461814A4 (en) | PROSTATE CANCER TREATMENT | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| ZA201304225B (en) | Methods of treating cancer | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| EP2501845A4 (en) | KREBSBIOMARKER | |
| EP2593100A4 (en) | METHOD OF TREATING REFRACTORY CANCER | |
| IL213919A0 (en) | Methods to treat cancer | |
| GB0916686D0 (en) | Treatment of cancer | |
| GB0921757D0 (en) | Treatment of cancer | |
| IL223237A0 (en) | Diagnosis of cancer | |
| GB201017354D0 (en) | Treatment of cancer | |
| GB201007977D0 (en) | Treatment of cardiovascular disease | |
| GB0906490D0 (en) | Use of tetanolic for treatment of breast cancer | |
| GB0908666D0 (en) | Treatment of proteostatic disease | |
| GB201017356D0 (en) | Combination treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |